NKAP and glioma: During the five-year follow-up period, the overall survival of the glioma patients with high-level NKAP expression was markedly lower than that of patients with low-level NKAP expression (Fig. 6d), suggesting that a high level of NKAP was associated with poor prognosis in a long round.